Ability of sextant biopsies to predict radical prostatectomy stage

Urology

Volumn 51, Issue 5, 1998, Pages 759-764

  Wills, Marcia L ^a   Sauvageot, Jurgita ^a   Partin, Alan W ^a   Gurganus, Robin ^a   Epstein, Jonathan I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; CARCINOMA; EVALUATION STUDIES; FORECASTING; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0031744760     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00011-9     Document Type: Article

References (30)

1. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers analysis of preoperative parameters . Urology. 44:1994;862-867.
2. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:1995;75-80.
3. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment value of systematic biopsies . J Urol. 156:1996;1059-1063.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
5. Humphrey PA, Bata J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer. 75:(suppl):1995;1842-1849.
6. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 153:1995;1543-1548.
7. Epstein JI, Carmichael M, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy a study of 196 cases with long-term followup . J Urol. 150:1993;135-141.
8. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 111:1974;58-64.
9. Oesterling JE. Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
10. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 269:1993;57-60.
11. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin B, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
12. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper UM, Walsh PC, McNeil GJ. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer results of a multi-institutional cooperative trial . N Engl J Med. 323:1990;621-626.
13. Palken M, Cobb OE, Warren BH, Hoak DC. Prostate cancer correlation with digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens . J Urol. 143:1990;1155-1162.
14. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Wittemore AS, Schmid HP. Localized prostate relationship of tumor volume to clinical significance for treatment of prostate cancer . Cancer. 71:(3 Suppl):1993;933-938.
15. Stamey TA, McNeal JE, Freiha FS, Redwine EA. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 139:1988;1235-1241.
16. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 150:1993;1845-1850.
17. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A, Toublanc M, Boccon-Gibod L. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology. 44:1994;371-376.
18. Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 45:1995;2-12.
19. Huland H, Hammerer P, Henke RP, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol. 155:1996;1344-1347.
20. Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies a preoperative evaluation of prostate cancer volume . Urology. 45:1995;987-992.
21. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:1995;75-80.
22. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies a histopathologic correlation with radical prostatectomy specimens . Cancer. 75:1995;530-538.
23. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view . J Urol. 157:1997;244-250.
24. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kouchie P, O'Dowd GJ, Veltri RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol. 156:1996;1375-1380.
25. Stroumbalis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 49:(suppl 3A):1997;113-118.
26. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Utility of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol. 158:1997;1886-1890.
27. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 141:1989;1076-1083.
28. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy Influence of clinical stage and tumor grade . Urology. 41:1993;207-216.
29. Partin AW, Yoo J, Carter HB, Pearson JK, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
30. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 138:1987;92-98.